HALIFAX, May 19 /CNW/ - Immunovaccine Inc., (TSX-V:IMV) a clinical stage
vaccine development company, is pleased to provide an update on recent
clinical research, business development and corporate activities.
Clinical Research Update
Immunovaccine has completed a pre-Investigational New Drug Application
(pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for
DPX-Survivac. DPX-Survivac is a therapeutic cancer vaccine candidate
that uses Survivin-based antigens (in-licensed from Merck KGaA)
formulated in the DepoVax™ vaccine delivery platform. While
DPX-Survivac has the potential to target at least nine different
cancers, for this initial clinical trial the Company is developing
DPX-Survivac to treat ovarian cancer.
In preclinical studies, DPX-Survivac was found to significantly enhance
immune response over the control formulation used in previous clinical
trials. The Company is completing the remaining safety studies required
for the IND filing for clearance to begin human clinical trials.
Signs Research Partnership with CIMAB S.A.
Immunovaccine announced today that it has signed a research agreement
with Cuban-based CIMAB S.A. In the agreement, the CIMAvax-EGF peptide
antigen will be formulated in Immunovaccine's DepoVax™ delivery system
to potentially enhance the immunogenicity of a novel therapeutic
CIMAB S.A. is devoted to the commercialization of biopharmaceutical
products for the Cuban market and abroad, especially monoclonal
antibodies and other recombinant proteins for the diagnosis and
treatment of cancer and other diseases related to the immune system.
CIMAB S.A. is the exclusive representative for the commercialization of
the products and services of the Center of Molecular Immunology (CIM).
In July 2008, CIM received approval from the Cuban regulatory
authorities for a lung cancer vaccine, targeting epidermal growth
factor (EGF), a protein that signals cancer cells to grow and divide
Retains The Equicom Group for Strategic Investor Relations Services
Effective May 16, 2011, Immunovaccine has retained The Equicom Group
Inc. ("Equicom") to provide strategic investor relations services.
Equicom provides strategic communications services to approximately 100
public companies across a diverse range of industries. Under the terms
of the agreement, Immunovaccine will pay Equicom a monthly fee
of $5,800 for select strategic communication services. The initial
contract term is six months and commences immediately.
Neither Equicom nor any of its principals have an ownership interest,
directly or indirectly, in Immunovaccine or its securities, nor has the
Company granted Equicom or its principals any rights to acquire any
such interests. Equicom is a wholly-owned subsidiary of TMX Group Inc.
About Immunovaccine Inc.
Immunovaccine Inc. (TSX-V:IMV) is a clinical stage vaccine development
company focused on the commercialization of its patented DepoVax™
vaccine delivery technology and product candidates. The Company
continues to strengthen its vaccine pipeline through licensing and
strategic partnerships to develop therapeutic cancer and infectious
disease vaccines. www.imvaccine.com
This press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is forward-looking
information. Forward-looking statements are based on the estimates and
opinions of management on the date the statements are made. However,
they should not be regarded as a representation that any of the plans
will be achieved. Actual results may differ materially from those set
forth in this press release due to risks affecting the Company,
including access to capital, the successful completion of clinical
trials and receipt of all regulatory approvals. Immunovaccine Inc.
assumes no responsibility to update forward-looking statements in this
press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE Immunovaccine Inc.
For further information:
Jennifer Ayotte, Director Communications, Immunovaccine Inc.
T: (902) 492-1819 E: email@example.com
Andrew Mielach, Tiberend Strategic Advisors, Inc.
T: (212) 827-0020 E: firstname.lastname@example.org